智通财经APP获悉，里昂发布研报称，康方生物(09926)产品销售同比增长25.3%，该行认为其AK104及AK112的销售情况应符合公司预期。公司管理层透露，自今年AK112被纳入国家医保药品目录(NRDL)以来，其销售实现不错的增长。该行将其目标价由72.1港元上调至95.3港元，维持“跑赢大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.